Jyong Biotech Ltd.
MENS Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.77
KIRA · Stoqly’s AI analyst, in plain words
- Jyong Biotech Ltd. lost $4.7M in fiscal 2025.
- Jyong Biotech Ltd. owes $16.3M more than it holds in cash.
Market cap
$129M
P/E
—
Revenue
—
Net income
−$4.7M
Free cash flow
—
Operating margin
—
Jyong Biotech Ltd. in 30 seconds · fiscal 2025
Does it make a profit?
−$4.7M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Jyong Biotech Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · May 15, 2026
- Legal name
- Jyong Biotech Ltd.
- CIK
- 0001954488
Jyong Biotech Ltd. · MENS
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$4.4M | −$3.0M | −$4.7M |
| Diluted EPS | −$0.06 | −$0.04 | −$0.06 |
| Cash | |||
| Cash from operations | −$2.6M | −$3.6M | −$3.0M |
| Share count change | — | 0.0% | 2.0% |
| Debt and strength | |||
| Cash and short-term investments | $1.7M | $0.1M | $1.2M |
| Debt incl. finance leases | — | — | $17.5M |
| Shareholders' equity | −$34.1M | −$36.5M | −$24.9M |
| Current ratio | — | 0.0x | 0.4x |
| Interest coverage | −3.7x | −2.0x | −1.0x |
| Returns and quality | |||
| Altman Z'' | — | −32.3 | −13.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Jyong Biotech Ltd. · MENS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.77 a share, the company is worth $129M.
Source: SEC EDGAR XBRL filings (CIK 0001954488). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.